Teva Pharmaceutical Industries CEO Jeremy Levin put manufacturing efficiencies at the heart of his plans for Teva to cut costs when he first announced his plans in December. Today he stepped on the gas.
Teva Pharmaceutical Industries is in the midst of devising a master plan to downsize its manufacturing network as CEO Jeremy Levin looks to carve $2 billion in annual costs out of the generics maker.
This year's revenue won't come in at the $22 billion previously projected, he said, and nor will the company be as profitable as earlier forecasts indicated.
Teva Pharmaceutical Industries ($TEVA), the Israeli generics giant, is reportedly mulling over the idea of jumping to the New York Stock Exchange after three decades of trading on Nasdaq, Haaretz is reporting.
Teva Pharmaceutical Industries ($TEVA) has been the world's biggest generics player for years. Problem is, it's trying to be more than that. And makeovers take time. Midway through last year,...
The changing of the guard at Teva Pharmaceutical Industries ($TEVA) couldn't more clearly signal a change in the generics giant's worldview. Under the current CEO, Shlomo Yanai, Teva more than